Norcantharidin is used in cancer research and treatment due to its antitumor properties. It has shown activity against liver, gastric, and bladder cancers by inducing apoptosis and inhibiting cell proliferation. Unlike its natural counterpart, it lacks severe kidney toxicity, making it a safer option for long-term therapy. It is also explored for its ability to enhance immune response against tumor cells. In clinical settings, it is administered to improve survival rates and reduce tumor recurrence after surgery. Additionally, it is studied for use in combination with chemotherapy to increase effectiveness and reduce drug resistance.